ReutersJohnson & Johnson on May 11 appointed Thibaut Mongon as the chief executive officer of the consumer health division, which the pharmaceutical giant plans to spin off into a listed company by the end of 2023.
Sanofi reported a series of first-quarter 2022 wins, driven mostly by the success of consumer healthcare (CHC) and the company’s blockbuster Dupixent.
GlaxoSmithKline exceeded expectations for the company’s first-quarter 2022 sales and earnings forecasts. This was largely driven by GSK’s sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and the company’s Shingrix vaccine against shingles.
Germany’s Bayer signed a deal to sell the company’s Dr. Scholl’s footcare brand to U.S. private investment firm Yellow Wood Partners for $585 million.
Sanofi will change the organizational structure of two Global Business Units to provide greater focus on operations in mature markets and across emerging markets.
Pfizer Inc. announced that the company is reviewing strategic alternatives for its Consumer Healthcare business.